Compounded medications are not FDA approved. FDA does not review compounded medications for safety, effectiveness, or quality before they are marketed.

Semaglutide · side effects

Semaglutide side effects: common, serious, and compounded-specific

The GI and serious side-effect profile of semaglutide from approved labeling, plus compounded-specific risks.

The most common semaglutide side effects are gastrointestinal — nausea, diarrhea, vomiting, and constipation — and are usually dose-related and most prominent during dose increases. Serious risks include a boxed warning for thyroid C-cell tumors (based on rodial studies) and rarer pancreatitis, gallbladder disease, and kidney injury from dehydration. These profiles come from the approved product; compounded semaglutide carries the same pharmacology plus added uncertainty about ingredient identity and purity.

Common adverse events

Most common adverse events with approved semaglutide (STEP 1-era labeling, % of patients)Nausea44Diarrhea30Vomiting24Constipation24Abdominal pain20

Most common adverse events with approved semaglutide (STEP 1-era labeling, % of patients) — approved labeled dosing; compounded/microdose products are not separately characterized

The chart reflects approved-product labeling. Gastrointestinal effects dominate and are usually manageable, but they are also the most common reason people stop treatment. Dehydration from vomiting or diarrhea is the mechanism behind several of the more serious downstream problems, which is why hydration and prompt clinical contact matter.

Semaglutide's gastrointestinal profile is the most extensively characterized of the two, with nausea reported in roughly 44% of patients at the weight-management dose, diarrhea around 30%, and vomiting near 24%. One semaglutide-specific monitoring point: in people with type 2 diabetes, worsening of diabetic retinopathy was observed in trials, so those with existing retinopathy are watched more closely as glucose falls. Its longer clinical experience also means its adverse-event signal is comparatively mature — fewer surprises, more published characterization.

Because semaglutide has a roughly week-long half-life, its side effects build and resolve slowly; a wave of nausea often follows a dose increase by a day or two and then eases. That slow pharmacology is part of why approved products escalate gradually and why a compounded semaglutide taken without that supervised escalation can still produce meaningful GI effects. And with compounded semaglutide, the salt-form question adds a wrinkle the approved drug does not have: an unexpected reaction could reflect a different active ingredient, not just a higher dose.

Serious risks and warnings

Serious risks in approved semaglutide labeling
RiskNotes
Boxed warning: thyroid C-cell tumorsBased on rodent studies; contraindicated with personal/family history of medullary thyroid carcinoma or MEN 2.
PancreatitisDiscontinue if suspected; evaluate for acute pancreatitis.
Gallbladder diseaseCholelithiasis has been reported; rapid weight loss is itself a risk factor.
HypoglycemiaMainly when combined with insulin or a sulfonylurea.
Acute kidney injuryUsually from dehydration due to vomiting/diarrhea.
Diabetic retinopathy complicationsMonitored in people with type 2 diabetes.
Compounded-specific caution. A compounded semaglutide adds risks the approved product does not: ingredient identity (including non-base salt forms), concentration accuracy, sterility, and labeling. Verify the dispensing pharmacy and confirm what active ingredient is supplied.

What the evidence shows

  • GI side effects are common with semaglutide and are dose-related.
  • Serious risks (boxed thyroid warning, pancreatitis, gallbladder, kidney) are documented for the approved product.

What the evidence does not show

  • That a microdose is free of side effects — lower doses reduce but do not eliminate risk.
  • That compounded products are quality-assured like the approved drug — they are not FDA reviewed.

Frequently asked questions

What are the most common semaglutide side effects?

Nausea, diarrhea, vomiting, and constipation, usually dose-related and worst during increases.

Does semaglutide have a boxed warning?

Yes — a boxed warning for thyroid C-cell tumors based on rodent studies; it is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2.

Are microdose side effects lower?

Lower doses generally cause fewer GI effects, but risk is not zero and serious warnings still apply.

If you are managing side effects, see what to do after side effects.

Not medical advice. This page is consumer education, not medical advice, and does not recommend a dose, product, or provider. Compounded medications are not FDA approved. Talk with a licensed clinician about your situation.